Revaprazan is a drug approved for use in Korea and India for the treatment of gastritis.
It acts as an acid pump antagonist and reduces the gastric acid secretion in the body.
Revaprazan is prescribed for the treatment of duodenal ulcer, gastric ulcer and gastritis.
Revaprazan is classified a reversible acid pump antagonist (APA or a potassium-competitive acid blocker) since it acts in a mechanism different from irreversible proton pump inhibitors, such as omeprazole.
Revaprazan is not dependent upon secretion status of a proton pump or acid activation of a drug in a stomach.
Revaprazan has long-lasting acid-suppressive effects. Revaprazan is approved for use only in Korea and India.
Revaprazan is contraindicated in patients hypersensitive to the drug.
The recommended dose of revaprazan is a 200mg tablet once daily.
Revaprazan should be taken 30 min before food.
• Caution should be taken during pregnancy and breastfeeding.
• Caution should be taken when giving the drug to patients with kidney and liver disease.
• Gastrointestinal: Diarrhea, nausea, abdominal pain, constipation, flatulence
• Central nervous system: Headache
• Others: Rhinorrhea
Avoid excess dose.
Revaprazan could reduce the absorption of drugs whose absorption is dependent on gastric pH, for example, ketoconazole
Should be stored at room temperature.
Subscribe to our Free Newsletters!